Summit announces approval for Phase 1 Clinical trial - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy

Summit announces approval for Phase 1 Clinical trial - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: Summit Corporation plc (‘Summit’ or ‘the Company’) SUMMIT RECEIVES REGULATORY APPROVAL TO ENTER SMT C1100 INTO A PHASE I CLINICAL TRIAL Oxford, UK, 24 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that its Phase I Clinical Trial Application (‘CTA’) for SMT C1100 has been approved by the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (‘MHRA’).